Docosahexaenoic acid/eicosapentaenoic acid/ - Sancilio and Company

Drug Profile

Docosahexaenoic acid/eicosapentaenoic acid/ - Sancilio and Company

Alternative Names: Eicosapentaenoic acid/docosahexaenoic acid – Sancilio and Company; SC 401

Latest Information Update: 06 Dec 2016

Price : $50

At a glance

  • Originator Sancilio & Company
  • Class Antihyperlipidaemics; Docosahexaenoic acids; Eicosanoids; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 22 Nov 2016 The US FDA places clinical hold on IND application for a phase III trial of SC 401 in Hypertriglyceridaemia (NCT01997268)
  • 22 Nov 2016 Sancilio and Company withdraws prior to enrolment a phase III trial in Hypertriglyceridemia in USA (NCT01997268)
  • 24 Feb 2016 Sancilio Pharmaceuticals receives patent allowance for SC 401 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top